Posted from: Wednesday, April 29, 2015 - 11:34 AM - Present

ProAir RespiClick Inhaler Approved

April 1, 2015 – The U.S. Food and Drug Administration (FDA) approved ProAir RespiClick, manufactured by Teva.  ProAir RespiClick is a dry-powder, breath-activated albuterol sulfate inhaler. It will be used by reversible obstructive airway disease patients who are at least 12 years old to prevent bronchspasms, including those induced by exercise, and to treat bronchospasms. Each inhaler, which contains 200 doses of albuterol, includes a dose counter to track how much has been used. Teva plans to introduce ProAir RespiClick in the second quarter of 2015.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

Last Updated Sunday, June 25, 2017 - 08:37 AM.